Author + information
- Received August 24, 2015
- Revision received November 4, 2015
- Accepted November 5, 2015
- Published online February 1, 2016.
- Sorin V. Pislaru, MD, PhD∗ (, )
- Vuyisile T. Nkomo, MD, MPH and
- Gurpreet S. Sandhu, MD, PhD
- ↵∗Reprint requests and correspondence:
Dr. Sorin V. Pislaru, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905.
Calcific aortic valve stenosis is a common valve pathology that increases in prevalence with advancing age. Transcatheter aortic valve (TAV) replacement has now emerged as the preferred treatment for patients at high risk for surgery and for those who are inoperable. However, the use of this ground-breaking technology has inevitably been associated with a host of new problems. These new types of complications are frequently unrecognized or underestimated due to lack of familiarity with the normal and pathological appearance of TAV and often require redefining strategies for diagnosis and treatment. This review presents a systematic approach for follow-up assessment of TAV function, as well as pathology uniquely related to TAV. Because the worldwide transcatheter aortic valve replacement experience has been dominated by the Edwards Sapien (Irvine, California) and Medtronic CoreValve (Minneapolis, Minnesota) family of bioprosthetic aortic valves, we will focus our review on these valves, each with their unique set of advantages and technological challenges.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 24, 2015.
- Revision received November 4, 2015.
- Accepted November 5, 2015.
- American College of Cardiology Foundation